GlaxoSmithKline’s 3TC, an experimental two-drug combination of dolutegravir and lamivudine, is a treatment for HIV that was found to be as effective as standard triple therapy, even in people with relatively high levels of the virus that causes AIDS, in a recent clinical study.
GSK's researchers found found 91 percent of patients taking the combo had high levels of viral control versus 93 percent of those on three drugs in the 48-week study with 1,400 patients.
By simplifying to a two-drug treatment, GSK will compete with rivals by reducing potential side effects and reducing costs.
Read the Reuters report